Today: Today, Brokers Set Expectations for BioDelivery Sciences International Inc.’s Q2 2017 Earnings (BDSI)

Today, Brokers Set Expectations for BioDelivery Sciences International Inc.’s Q2 2017 Earnings (BDSI)

BioDelivery Sciences International Inc. (NASDAQ:BDSI) – Research analysts at Roth Capital lowered their Q2 2017 EPS estimates for BioDelivery Sciences International in a report released on Monday. Roth Capital analyst S. Henry now expects that the brokerage will post earnings per share of ($0.19) for the quarter, down from their previous forecast of ($0.18). Roth Capital has a “Buy” rating and a $7.00 price target on the stock.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.04. BioDelivery Sciences International had a negative return on equity of 309.49% and a negative net margin of 93.61%. The company had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $3.58 million. During the same quarter in the previous year, the business earned ($0.39) EPS. The company’s revenue for the quarter was up 200.0% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reiterated a “hold” rating on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Piper Jaffray Cos. reiterated a “sell” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Tuesday, October 25th. FBR & Co reiterated a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 20th. Finally, Janney Montgomery Scott upgraded shares of BioDelivery Sciences International from a “neutral” rating to a “buy” rating and boosted their price target for the company from $2.45 to $4.00 in a research report on Friday, September 23rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $6.57.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) opened at 1.75 on Wednesday. The stock’s market cap is $94.71 million. The stock’s 50 day moving average is $2.18 and its 200 day moving average is $2.38. BioDelivery Sciences International has a 52 week low of $1.50 and a 52 week high of $6.40.

Several hedge funds and other institutional investors have recently modified their holdings of the company. KCG Holdings Inc. increased its position in shares of BioDelivery Sciences International by 235.8% in the third quarter. KCG Holdings Inc. now owns 39,347 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 27,630 shares in the last quarter. NEXT Financial Group Inc increased its position in shares of BioDelivery Sciences International by 42.4% in the third quarter. NEXT Financial Group Inc now owns 49,850 shares of the specialty pharmaceutical company’s stock valued at $135,000 after buying an additional 14,850 shares in the last quarter. Alpine Partners VI LLC purchased a new position in shares of BioDelivery Sciences International during the second quarter valued at about $147,000. Krilogy Financial LLC purchased a new position in shares of BioDelivery Sciences International during the second quarter valued at about $164,000. Finally, Bank of New York Mellon Corp increased its position in shares of BioDelivery Sciences International by 9.9% in the third quarter. Bank of New York Mellon Corp now owns 62,945 shares of the specialty pharmaceutical company’s stock valued at $170,000 after buying an additional 5,677 shares in the last quarter. Hedge funds and other institutional investors own 60.65% of the company’s stock.

In other news, Director Francis E. Odonnell, Jr. sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 23rd. The shares were sold at an average price of $2.57, for a total value of $257,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Niraj Vasisht sold 47,000 shares of the company’s stock in a transaction that occurred on Friday, September 23rd. The stock was sold at an average price of $2.43, for a total transaction of $114,210.00. Following the completion of the transaction, the insider now owns 73,081 shares in the company, valued at approximately $177,586.83. The disclosure for this sale can be found here. 9.00% of the stock is currently owned by insiders.

BioDelivery Sciences International Company Profile

Related posts

Leave a Comment